Yeda Research and Develpment & Co. Ltd

Wisconsin Alumni Research Foundation

Other

The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Benjamin Geiger

Paul L Kaufman

Zvi Kam

Zelig Eshhar

Varda Rotter

Tova Waks

Moshe Oren

Anat Globerson Levin

Nir Friedman

Alexander Bershadsky

Teresa Borras

Irina Lavelin

Shimrit Lieber

Ami Navon

Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.

Methods of culturing t cells and uses of same

A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Proteasome inhibitors and uses thereof

A polynucleotide encoding a chimeric polypeptide is provided. The chimeric polypeptide includes (a) a first polypeptide region being capable of specifically binding at least one detectable molecule; and (b) a second polypeptide region being capable of specifically binding a biological component or macromolecule or targeting a cellular compartment. Methods utilizing the polynucleotide or the chimeric polypeptide for highlighting a cell compartment, a biological component or macromolecule are also provided.

AKAP84 and its use for visualization of biological structures

A method for reducing intraocular pressure and increasing outflow facility from an eye of a subject having glaucoma includes the step of providing in the trabecular meshwork of the eye an amount of caldesmon effective to reduce intraocular pressure and increase outflow facility.

Method for treating glaucoma

An auto-focusing method and device are presented for determining an in-focus position of a sample supported on a substrate plate made of a material transparent with respect to incident electromagnetic radiation. The method utilizes an optical system capable of directing incident electromagnetic radiation towards the sample and collecting reflections of the incident electromagnetic radiation that are to be detected. A focal plane of an objective lens arrangement is located at a predetermined distance from a surface of the substrate, which is opposite to the sample-supporting surface of the substrate. A continuous displacement of the focal plane relative to the substrate along the optical axis of the objective lens arrangement is provided, while concurrently directing the incident radiation towards the sample through the objective lens arrangement to thereby focus the incident radiation to a location at the focal plane of the objective lens arrangement. Reflected components of the electromagnetic radiation to a location objective lens arrangement are continuously detected. The detected reflected components are characterized by a first intensity peak corresponding to an in-focus position of said opposite surface of the substrate, and a second intensity peak spaced in time from the first intensity peak and corresponding to an in-focus position of said sample-supporting surface of the substrate. This technique enables imaging of the sample when in the in-focus position of the sample-supporting surface of the substrate.

Auto-focusing method and device for use with optical microscopy

Methods for the treatment of glaucoma are provided by the present invention. The compounds described cause a perturbation of the actin cytoskeleton in the trabecular meshwork or the modulation of its interactions with the underlying membrane. Perturbation of the cytoskeleton and the associated adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.

Cytoskeletal active agents for glaucoma therapy

Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.

Growing community of inventors

Rehovot, Israel

Benjamin Geiger